glp 1 and gip dual agonist GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica Dual GLP-1/GIP Agonist | Tirzepatide

soi: 10.1056/nejmoa2505669

Hence, empagliflozin is not commonly used as a routine treatment for type 1 diabetes but is mainly approved to treat type 2 diabetes

In addition to the different study populations and study design in these trials, one potential reason for this heterogeneity in cardiovascular benefit is the structural differences among the GLP-1RAs used in these trials

Antagonizing GIPR adds fire to the GLP-1R flame

Acknowledgements This work was supported by research grants from the National Key Research and Development Program of China (2016YFA0100501), the Chinese National 973 Program (2012CB517502), the National Natural Sciences Foundation of China (81400798, 81400767, 81401142, 81270858, and 81570692), and the Beijing Natural Sciences Foundation of China (7163233)